

Randox Laboratories Ltd 55 Diamond Road Crumlin United Kingdom BT29 4QY technical.services@randox.com Tel: +44 (0) 28 9445 1070

Date Issued: 11 December 2019

Complaint Reference: REC430

Action Type: Device Modification

### **Detail on Affected Devices:**

Our records indicate that your facility may have received the following product

Device Name	Catalogue Number	GTIN	Batch / Lot number	Expiry Date	Manufacturing Date
Liquid Clinical Chemistry Control	LAE4217	05055273208993	1021UE	30 Jun 2020	21 Oct 2018

#### Reason for Action:

A transcription error has occurred for the Randox Lipase colorimetric value in Liquid Clinical Chemistry Control lot 1021UE. The target and range are listed as 50 U/L (40 - 60) and should be 72U/L (58 - 86).

### Risk to Health:

Control falling out of range could lead to a delay in reporting patient results. See attached HHE.

#### Action to be taken:

- Update the affected kits with the correct target values provided.
- Discuss the contents of this notice with your Medical Director.
- Complete and return the response form 12187-QA to <u>technical.services@randox.com</u> within five working days.

Last printed: 11 December 2019



Randox Laboratories Ltd 55 Diamond Road Crumlin United Kingdom BT29 4QY technical.services@randox.com Tel: +44 (0) 28 9445 1070

## **Transmission of Field Safety Notice**:

Send a copy of the FSN to all affected customers and to those who need to be aware within your organisation.

Please accept our apologies for any inconvenience caused. Thank you for your patience and understanding. If you have any questions or concerns please contact Randox Technical Services.

The undersigned confirms that this notice has been notified to the appropriate Regulatory Agency

E.

Last printed: 11 December 2019



Date Issued: 11 December 2019

Randox Laboratories Ltd 55 Diamond Road, Crumlin United Kingdom BT29 4QY technical.services@randox.com

Tel: +44 (0) 28 9445 1070

## Please complete this form even if you do not have any affected stock.

Complaint Reference: REC430			Action Type: Device Modification			
Detail on Affec	ted Devices:					
Our records indi	Our records indicate that your facility may have received the following product					
Device Name	Catalogue Number	GTIN	Batch / Lot number	Expiry Date	Manufacturing Date	
Liquid Clinical Chemistry Control	LAE4217	05055273208993	1021UE	30 Jun 2020	21 Oct 2018	
I have chell land land land land land land land la	ead and undersonecked my sto obtified all those fety Notice is retion of affected ted stock and (specify quanted (specify qua	stand the instruction of the control	ne affected kits aware of this no y use of the production of the production of the form of the distribution of the distributio	otice within the coduct.		
Customer Detail	ls					
Company Nam	ie					

Address



Randox Laboratories Ltd
55 Diamond Road, Crumlin
United Kingdom BT29 4QY
technical.services@randox.com

Tel: +44 (0) 28 9445 1070

Total Quantity			
Received			
Distributed			
Completed By	Print Name:	Date	
	Signature:		
Contact Telephone		ı	
Contact Email			

Complete and return the response form to <a href="technical.services@randox.com">technical.services@randox.com</a> within five working days.

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your regulatory authority requires your response form as evidence of the effectiveness of the corrective actions detailed in the FSN.



Randox Laboratories Ltd 55 Diamond Road, Crumlin United Kingdom BT29 4QY technical.services@randox.com

Tel: +44 (0) 28 9445 1070

# PART 2 (To be completed by Distributors and Randox Offices only)

Area of Distribution	n				
	ied and notified my product by (specify			ay have been	
OR					
Detailed below is a list of customers who received/may have received this product. Please notify my customers. (List of customers may also be sent in a separate attachment)					
Consignee	Country	Quantity Received	Analyser / Kit Serial / Lot Number	Replacements Required	
Have your customers YES NO If yes, please explain		y adverse events a	ssociated with re	called product?	